Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6610 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-20 (biospace.com)
Spinal muscular atrophy -
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of its Ionis-partnered therapy Spinraza for spinal muscular atrophy will be considered by the FDA and EMA.
Read more
2025-03-18 (biopharmadive.com)
Stoke CEO exits; Medicare drug price talks advance |
Ed Kaye, Stoke's longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.
Read more
2024-10-09 (marketwatch.com)
Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about...
Read more
2023-01-18 (fiercepharma.com)
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Once again, biopharma companies offered hefty discounts to secure national reimbursement in China in the hopes that wider coverage in a fast-growing pharmaceutical market can offset price concessio| Innovative drugs from AbbVie, Novartis and Roche are among 111 therapies that won China 's national
Read more
2021-06-15 (fiercepharma.com)
Despite controversy, Biogen's Aduhelm is already generating enthusiasm among doctors: survey |
Biogen's Aduhelm may have stirred up controversy after its landmark FDA approval, but some Alzheimer's disease doctors are tabling the many unanswered questions as they appear rea | Biogen's Aduhelm may have stirred up controversy after its landmark FDA approval, but some Alzheimer's doctors are tabling the many unanswered questions as they appear ready to prescribe the drug in a potentially megablockbuster windfall for the biotech.
Read more